心脏糖化物毒性:近期研究中的机制和缓解策略
Shuyun Xiao1, Mengqi Tong1, Jiayi Ren1
1Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, China.
Chemico-biological interactions
|November 12, 2025
概括
心脏糖化物对癌症治疗有希望,但会引起严重的心脏毒性. 本综述探讨了减少毒性的机制,管理和策略,以实现更安全的药物开发.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 毒理学 毒理学 毒理学
背景情况:
- 心脏糖化物具有心性质和新兴的抗瘤潜力.
- 它们的临床应用受到狭窄的治疗窗口和显著的心脏毒性限制.
- 最近的进展包括RX108等衍生品进入癌症临床试验.
研究的目的:
- 审查了解和减轻心脏糖化物诱导的心脏毒性的最新进展.
- 为了总结超出Na+/K+-ATPase抑制的心脏毒性分子机制.
- 分析结构修改策略,以将疗效与毒性分开.
主要方法:
- 关于心脏糖化物研究近期进展的文献综述.
- 对心脏毒性的分子机制的分析.
- 检查多器官毒性概况和临床管理.
- 对结构修改策略的批判性评估.
主要成果:
- 心脏毒性机制复杂,不仅涉及Na+/K+-ATPase抑制.
- 多器官毒性需要特殊的临床管理,包括毒素特异性Fab抗体.
- 合理的结构修改显示出将心脏毒性与疗效脱的潜力.
结论:
- 了解复杂的毒性机制对于安全的药物开发至关重要.
- 需要有针对性的策略来克服心脏糖化物毒性障碍.
- 在精密瘤学中重新利用心脏糖化物需要解决安全问题.
相关概念视频
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
Dysrhythmias VI: Management of Dysrhythmias
422
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
422
Cardiomyopathy II: Dilated Cardiomyopathy
451
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
451
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Heart Failure II: Pathophysiology
695
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
695


